SOURCE: Lantheus Medical Imaging, Inc.

Lantheus Medical Imaging, Inc.

April 21, 2015 16:15 ET

Lantheus to Host First Quarter 2015 Earnings Conference Call on May 5, 2015 at 4:30 p.m. Eastern Time

N. BILLERICA, MA--(Marketwired - April 21, 2015) - Lantheus Medical Imaging, Inc. (Lantheus) today announced that it will host a conference call at 4:30 p.m. ET on Tuesday, May 5, 2015, to discuss its financial and operating results for the first quarter of 2015.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 30201918. A live audio webcast of the call also will be available on the homepage of the Company's website at www.lantheus.com.

A replay of the telephone conference call and audio webcast will be available from approximately 8:30 p.m. ET on May 5, 2015 through midnight on May 19, 2015. To access a replay of the conference call, dial 1-855-859-2056 (U.S. callers) or 1-404-537-3406 (international callers), and provide passcode 30201918.

About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc. is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents and products. The Company provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. Lantheus' key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc-99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon Xe-133 Gas (Xenon-133), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.

Lantheus has more than 500 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.

The following files are available for download:

Contact Information

  • CONTACTS:

    Investor Relations
    John Bakewell
    978-436-7073 

    Media Relations
    Meara Murphy
    978-671-8508